Abstract
<h3>Objective:</h3> To determine if PET/CT is abnormal in less differentiated forms of autoimmune encephalitis (AE), including seronegative AE and steroid-responsive encephalopathy with associated thyroiditis (SREAT), and whether specific patterns of dysmetabolism exist. <h3>Background:</h3> Brain <sup>18</sup>F-FDG PET/CT (PET) has been established as a useful tool in evaluating AE. Specific patterns of dysmetabolism have been identified in patients with anti-N-methyl-D-aspartate (NMDA) and anti-leucine-rich-glioma-inactivated-1 (LGI-1) AE, and preliminary evidence suggests that PET dysmetabolism may correlate with clinical functional status. <h3>Design/Methods:</h3> We conducted a retrospective cross-sectional analysis of PET scans in people with seronegative AE and SREAT. Utilizing NeuroQ™ software, the Z-scores of 47 brain regions were calculated compared to healthy controls, displayed in heat maps, and visually and statistically compared between study groups and to previous data from NMDA and LGI1 cohorts. <h3>Results:</h3> Sixteen seronegative AE and 4 SREAT patients were identified. All PET scans demonstrated abnormal FDG uptake, while MRI, EEG and CSF were abnormal less frequently in both groups. Both seronegative and SREAT patients demonstrated hypometabolism in the medial frontal, inferior frontal and parieto-temporal regions, and hypermetabolism in the medial temporal lobes. Regions of dysmetabolism were significantly different from NMDA and LGI1 patient data, an effect driven by greater severity of dysmetabolism in the NMDA and LGI1 patients. Follow up scans for 3 seronegative AE patients suggest the degree of dysmetabolism on PET correlates with functional status. <h3>Conclusions:</h3> PET is a useful tool in the evaluation of autoimmune encephalitis. SREAT and seronegative AE represent less differentiated forms of AE. Though frequently abnormal, as anticipated, the pattern of dysmetabolism in SREAT and seronegative AE were less distinct than in NMDA and LGI-1. The pattern of dysmetabolism observed here in SREAT patients was not markedly distinct from seronegative AE patients, potentially supporting consideration of SREAT as a type of seronegative AE rather than a distinct disease entity. <b>Disclosure:</b> Dr. Roman has nothing to disclose. Dr. Sadaghiani has nothing to disclose. Dr. Diaz-Arias has nothing to disclose. Marion Le Marechal has nothing to disclose. Dr. Venkatesan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceuticals. The institution of Dr. Venkatesan has received research support from NIH. The institution of Dr. Venkatesan has received research support from MSRCF. The institution of Dr. Venkatesan has received research support from U.S. DOD. Dr. Probasco has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch Neurology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
